Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
about
Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationValganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacyOral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.Management of cytomegalovirus infection and disease in liver transplant recipients.Current concepts on cytomegalovirus infection after liver transplantationOral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy.Strategies for the prevention of infection after solid organ transplantation.Two strategies for prevention of cytomegalovirus infections after liver transplantation.Prevention and management of cytomegalovirus infection in solid-organ transplantation.Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature.Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis.Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.Cytomegalovirus infection-associated fulminant hepatitis in an immunocompetent adult requiring emergency living-donor liver transplantation: report of a case.Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.Cytomegalovirus infection after liver transplantation: current concepts and challenges.Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus or Epstein Barr virus infections in the setting of pre-emptive therapy.A survey of CMV prevention strategies after liver transplantation.Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.Impact of the duration of posttransplant renal replacement therapy on bacterial infections in liver transplant recipients.
P2860
Q26826856-FE53FF7F-5E3A-436F-87DC-8F6A802D01FCQ28475480-B8A43FB5-7A1E-43EE-BA4A-DE4135B1DFCEQ33375027-63FDF280-9F20-4D74-98F8-4425822DB662Q33845124-5C410908-4D51-40F7-9397-4281B2963097Q34390310-F4D47C1B-93DA-48B0-B8CF-D573CA2B72D8Q35571656-352B946C-1C5D-4601-B648-1880736F53FFQ36344173-07317B1B-B6B5-4CC5-951A-0D9F5E95A2BBQ36670902-B75D3B24-B2F4-4C75-8776-2564AADB4E61Q36724385-A8229D81-DDA8-4F36-8617-B3318CAF2F8CQ36777860-B1DFFEB3-9643-429D-A2AC-10FD2848D7BCQ37034498-5F3DECB1-63E2-4716-9155-9CA122242AE8Q38293175-0547444E-9630-4336-822B-959EAB0CBC9FQ38364698-7B640DCE-581D-42FF-A345-C00EE353804BQ38460609-78A64320-3E05-4B97-BDCB-62CD07A35046Q38475761-89715CF2-3BF4-43B9-92EF-308E53F83E71Q39405795-039153D8-D4BA-44BE-8991-4B36BE43E830Q41500588-1CF52B78-E7E3-4967-A1E3-E05D0A13F122Q42549311-7E779A8A-5F89-47EC-9F08-26E2DE048498Q44100013-E01892D7-8C06-47EF-95BB-7D4D13CE76ECQ45388439-B25DBE4C-094E-49B6-9910-2645643CB106Q46921329-6A7356C6-5ACB-402C-BF55-18ABB3C30EB2Q46963345-C0F4E4AD-8928-42F5-B8DB-21FC6139F7D6Q48829443-45AD87F4-613E-4EA7-9C24-FFA16F426200
P2860
Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Efficacy of valganciclovir adm ...... onset cytomegalovirus disease.
@en
Efficacy of valganciclovir adm ...... onset cytomegalovirus disease.
@nl
type
label
Efficacy of valganciclovir adm ...... onset cytomegalovirus disease.
@en
Efficacy of valganciclovir adm ...... onset cytomegalovirus disease.
@nl
prefLabel
Efficacy of valganciclovir adm ...... onset cytomegalovirus disease.
@en
Efficacy of valganciclovir adm ...... onset cytomegalovirus disease.
@nl
P2093
P1433
P1476
Efficacy of valganciclovir adm ...... onset cytomegalovirus disease.
@en
P2093
Cheryl Wannstedt
Lois Keyes
Marilyn M Wagener
Nina Singh
Thomas V Cacciarelli
Timothy Gayowski
P356
10.1097/01.TP.0000146844.65273.62
P577
2005-01-01T00:00:00Z